{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:50:01Z","timestamp":1794336601700,"version":"4.9.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-70898-y","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:36:12Z","timestamp":1773891372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["DC-CD4 bispecific tolerogenic nanovesicles induce antigen-specific regulatory T cells and ameliorate collagen-induced arthritis in mice"],"prefix":"10.1038","volume":"17","author":[{"given":"Lei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunli","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6545-7867","authenticated-orcid":false,"given":"Yiran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4613-2893","authenticated-orcid":false,"given":"Xinyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"70898_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","volume":"24","author":"JE Kenison","year":"2024","unstructured":"Kenison, J. E., Stevens, N. A. & Quintana, F. J. Therapeutic induction of antigen-specific immune tolerance. Nat. Rev. Immunol. 24, 338\u2013357 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"70898_CR2","first-page":"532","volume":"15","author":"S Crunkhorn","year":"2016","unstructured":"Crunkhorn, S. Autoimmune disease: re-establishing immune tolerance. Nat. Rev. Drug. Discov. 15, 532 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"70898_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","volume":"9","author":"Y Song","year":"2024","unstructured":"Song, Y., Li, J. & Wu, Y. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct. Target. Ther. 9, 263 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70898_CR4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41551-025-01373-0","volume":"9","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Generation of tolerogenic antigen-presenting cells in vivo via the delivery of mRNA encoding PDL1 within lipid nanoparticles. Nat. Biomed. Eng. 9, 1320\u20131334 (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"70898_CR5","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41551-023-01086-2","volume":"7","author":"AC Tremain","year":"2023","unstructured":"Tremain, A. C. et al. Synthetically glycosylated antigens for the antigen-specific suppression of established immune responses. Nat. Biomed. Eng. 7, 1142\u20131155 (2023).","journal-title":"Nat. Biomed. Eng."},{"key":"70898_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo5284","volume":"8","author":"HS Sohn","year":"2022","unstructured":"Sohn, H. S. et al. Tolerogenic nanoparticles induce type II collagen-specific regulatory T cells and ameliorate osteoarthritis. Sci. Adv. 8, eabo5284 (2022).","journal-title":"Sci. Adv."},{"key":"70898_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35263-9","volume":"13","author":"TL Nguyen","year":"2022","unstructured":"Nguyen, T. L. et al. Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance. Nat. Commun. 13, 7449 (2022).","journal-title":"Nat. Commun."},{"key":"70898_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jconrel.2024.01.018","volume":"366","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. Transdermally delivered tolerogenic nanoparticles induced effective immune tolerance for asthma treatment. J. Control. Release 366, 637\u2013649 (2024).","journal-title":"J. Control. Release"},{"key":"70898_CR9","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1021\/acsnano.9b01444","volume":"13","author":"Q Liu","year":"2019","unstructured":"Liu, Q. et al. Use of polymeric nanoparticle platform targeting the liver to induce Treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization model. ACS Nano 13, 4778\u20134794 (2019).","journal-title":"ACS Nano"},{"key":"70898_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136774","volume":"131","author":"Y Tian","year":"2021","unstructured":"Tian, Y. et al. Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction. J. Clin. Invest. 131, e136774 (2021).","journal-title":"J. Clin. Invest."},{"key":"70898_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","volume":"395","author":"B Sawitzki","year":"2020","unstructured":"Sawitzki, B. et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials. Lancet 395, 1627\u20131639 (2020).","journal-title":"Lancet"},{"key":"70898_CR12","doi-asserted-by":"publisher","first-page":"115141","DOI":"10.1016\/j.addr.2023.115141","volume":"203","author":"BL Scotland","year":"2023","unstructured":"Scotland, B. L. et al. Cell and biomaterial delivery strategies to induce immune tolerance. Adv. Drug Deliv. Rev. 203, 115141 (2023).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"70898_CR13","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nri.2017.75","volume":"17","author":"L Lu","year":"2017","unstructured":"Lu, L., Barbi, J. & Pan, F. The regulation of immune tolerance by FOXP3. Nat. Rev. Immunol. 17, 703\u2013717 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"70898_CR14","doi-asserted-by":"publisher","first-page":"19446","DOI":"10.1073\/pnas.0706832104","volume":"104","author":"MM Tiemessen","year":"2007","unstructured":"Tiemessen, M. M. et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes\/macrophages. Proc. Natl Acad. Sci. USA 104, 19446\u201319451 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"70898_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar, M. & Hafler, D. A. Regulatory T cells in autoimmune disease. Nat. Immunol. 19, 665\u2013673 (2018).","journal-title":"Nat. Immunol."},{"key":"70898_CR16","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-025-02326-4","volume":"10","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduct. Target. Ther. 10, 345 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"70898_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41573-024-01089-x","volume":"24","author":"CM Wardell","year":"2025","unstructured":"Wardell, C. M., Boardman, D. A. & Levings, M. K. Harnessing the biology of regulatory T cells to treat disease. Nat. Rev. Drug Discov. 24, 93\u2013111 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70898_CR18","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transplant. 17, 931\u2013943 (2017).","journal-title":"Am. J. Transplant."},{"key":"70898_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaut.2018.05.003","volume":"92","author":"YC Kim","year":"2018","unstructured":"Kim, Y. C. et al. Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells. J. Autoimmun. 92, 77\u201386 (2018).","journal-title":"J. Autoimmun."},{"key":"70898_CR20","doi-asserted-by":"publisher","first-page":"103051","DOI":"10.1016\/j.jaut.2023.103051","volume":"138","author":"L Passeri","year":"2023","unstructured":"Passeri, L. et al. Tolerogenic IL-10-engineered dendritic cell-based therapy to restore antigen-specific tolerance in T cell mediated diseases. J. Autoimmun. 138, 103051 (2023).","journal-title":"J. Autoimmun."},{"key":"70898_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/JLB.3MA0921-219RRRR","volume":"110","author":"X Zhou","year":"2021","unstructured":"Zhou, X. et al. Adoptive transfer of GRP78-treated dendritic cells alleviates insulitis in NOD mice. J. Leukoc. Biol. 110, 1023\u20131031 (2021).","journal-title":"J. Leukoc. Biol."},{"key":"70898_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin, C., Vo, L. T. & Bluestone, J. A. T(reg) cell-based therapies: challenges and perspectives. Nat. Rev. Immunol. 20, 158\u2013172 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"70898_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LMR Ferreira","year":"2019","unstructured":"Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749\u2013769 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70898_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1136\/annrheumdis-2018-214024","volume":"78","author":"CH Mosanya","year":"2019","unstructured":"Mosanya, C. H. & Isaacs, J. D. Tolerising cellular therapies: what is their promise for autoimmune disease? Ann. Rheum. Dis. 78, 297\u2013310 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"70898_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41565-020-00810-2","volume":"16","author":"A Cifuentes-Rius","year":"2021","unstructured":"Cifuentes-Rius, A., Desai, A., Yuen, D., Johnston, A. P. R. & Voelcker, N. H. Inducing immune tolerance with dendritic cell-targeting nanomedicines. Nat. Nanotechnol. 16, 37\u201346 (2021).","journal-title":"Nat. Nanotechnol."},{"key":"70898_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1126\/science.aay3638","volume":"371","author":"C Krienke","year":"2021","unstructured":"Krienke, C. et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science 371, 145\u2013153 (2021).","journal-title":"Science"},{"key":"70898_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"ME Goebeler","year":"2024","unstructured":"Goebeler, M. E., Stuhler, G. & Bargou, R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat. Rev. Clin. Oncol. 21, 539\u2013560 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"70898_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug. Discov. 23, 301\u2013319 (2024).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"70898_CR29","doi-asserted-by":"publisher","first-page":"eaba8564","DOI":"10.1126\/sciadv.aba8564","volume":"6","author":"KM Au","year":"2020","unstructured":"Au, K. M., Park, S. I. & Wang, A. Z. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci. Adv. 6, eaba8564 (2020).","journal-title":"Sci. Adv."},{"key":"70898_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50474-y","volume":"15","author":"QN Ye","year":"2024","unstructured":"Ye, Q. N. et al. Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity. Nat. Commun. 15, 6211 (2024).","journal-title":"Nat. Commun."},{"key":"70898_CR31","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41565-024-01736-9","volume":"19","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy. Nat. Nanotechnol. 19, 1558\u20131568 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"70898_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41586-024-08279-y","volume":"637","author":"MW Kim","year":"2025","unstructured":"Kim, M. W. et al. Endogenous self-peptides guard immune privilege of the central nervous system. Nature 637, 176\u2013183 (2025).","journal-title":"Nature"},{"key":"70898_CR33","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2016.07.006","volume":"166","author":"J van der Veeken","year":"2016","unstructured":"van der Veeken, J. et al. Memory of inflammation in regulatory T cells. Cell 166, 977\u2013990 (2016).","journal-title":"Cell"},{"key":"70898_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41563-024-01865-5","volume":"23","author":"L Li","year":"2024","unstructured":"Li, L. et al. A DNA origami device spatially controls CD95 signalling to induce immune tolerance in rheumatoid arthritis. Nat. Mater. 23, 993\u20131001 (2024).","journal-title":"Nat. Mater."},{"key":"70898_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/ncprheum0559","volume":"3","author":"D Lainer-Carr","year":"2007","unstructured":"Lainer-Carr, D. & Brahn, E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat. Clin. Pract. Rheumatol. 3, 434\u2013442 (2007).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"70898_CR36","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen, J. S., Aletaha, D. & McInnes, I. B. Rheumatoid arthritis. Lancet 388, 2023\u20132038 (2016).","journal-title":"Lancet"},{"key":"70898_CR37","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha, D. & Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. JAMA 320, 1360\u20131372 (2018).","journal-title":"JAMA"},{"key":"70898_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-024-01190-w","volume":"21","author":"JT Schnell","year":"2025","unstructured":"Schnell, J. T. et al. The \u2018T(reg) paradox\u2019 in inflammatory arthritis. Nat. Rev. Rheumatol. 21, 9\u201321 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"70898_CR39","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1007\/s13555-025-01530-y","volume":"15","author":"Y Srinoulprasert","year":"2025","unstructured":"Srinoulprasert, Y. et al. A pilot study of differences in antibody responses of intradermal and intramuscular injections of botulinum toxin type A. Dermatol. Ther. 15, 3347\u20133360 (2025).","journal-title":"Dermatol. Ther."},{"key":"70898_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrd818","volume":"1","author":"H Schellekens","year":"2002","unstructured":"Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1, 457\u2013462 (2002).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70898_CR41","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e3015","volume":"76","author":"F Valenzuela","year":"2021","unstructured":"Valenzuela, F. & Flores, R. Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics 76, e3015 (2021).","journal-title":"Clinics"},{"key":"70898_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fimmu.2014.00046","volume":"5","author":"BD Singer","year":"2014","unstructured":"Singer, B. D., King, L. S. & D\u2019Alessio, F. R. Regulatory T cells as immunotherapy. Front. Immunol. 5, 46 (2014).","journal-title":"Front. Immunol."},{"key":"70898_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/cei\/uxac105","volume":"211","author":"F Harris","year":"2023","unstructured":"Harris, F., Berdugo, Y. A. & Tree, T. IL-2-based approaches to Treg enhancement. Clin. Exp. Immunol. 211, 149\u2013163 (2023).","journal-title":"Clin. Exp. Immunol."},{"key":"70898_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/immhor\/vlaf005","volume":"9","author":"JF Scheid","year":"2025","unstructured":"Scheid, J. F. et al. Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. Immunohorizons 9, vlaf005 (2025).","journal-title":"Immunohorizons"},{"key":"70898_CR45","doi-asserted-by":"publisher","first-page":"111478","DOI":"10.1016\/j.celrep.2022.111478","volume":"41","author":"D VanDyke","year":"2022","unstructured":"VanDyke, D. et al. Engineered human cytokine\/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. Cell Rep. 41, 111478 (2022).","journal-title":"Cell Rep."},{"key":"70898_CR46","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1021\/nn405033r","volume":"8","author":"Z Hunter","year":"2014","unstructured":"Hunter, Z. et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano 8, 2148\u20132160 (2014).","journal-title":"ACS Nano"},{"key":"70898_CR47","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jaut.2017.12.010","volume":"89","author":"S Prasad","year":"2018","unstructured":"Prasad, S. et al. Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J. Autoimmun. 89, 112\u2013124 (2018).","journal-title":"J. Autoimmun."},{"key":"70898_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.gastro.2021.03.014","volume":"161","author":"CP Kelly","year":"2021","unstructured":"Kelly, C. P. et al. TAK-101 nanoparticles induce gluten-specific tolerance in celiac disease: a randomized, double-blind, placebo-controlled study. Gastroenterology 161, 66\u201380.e68 (2021).","journal-title":"Gastroenterology"},{"key":"70898_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202400237","volume":"14","author":"MN Saunders","year":"2025","unstructured":"Saunders, M. N. et al. Allergen-encapsulating nanoparticles reprogram pathogenic allergen-specific Th2 cells to suppress food allergy. Adv. Healthc. Mater. 14, e2400237 (2025).","journal-title":"Adv. Healthc. Mater."},{"key":"70898_CR50","doi-asserted-by":"publisher","first-page":"20206","DOI":"10.1021\/acsnano.2c05643","volume":"16","author":"KA Brzezicka","year":"2022","unstructured":"Brzezicka, K. A. et al. Suppression of autoimmune rheumatoid arthritis with hybrid nanoparticles that induce B and T cell tolerance to self-antigen. ACS Nano 16, 20206\u201320221 (2022).","journal-title":"ACS Nano"},{"key":"70898_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44308-6","volume":"15","author":"J Middelburg","year":"2024","unstructured":"Middelburg, J. et al. T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors. Nat. Commun. 15, 48 (2024).","journal-title":"Nat. Commun."},{"key":"70898_CR52","doi-asserted-by":"publisher","first-page":"887402","DOI":"10.3389\/fphar.2022.887402","volume":"13","author":"J McCright","year":"2022","unstructured":"McCright, J., Naiknavare, R., Yarmovsky, J. & Maisel, K. Targeting lymphatics for nanoparticle drug delivery. Front. Pharmacol. 13, 887402 (2022).","journal-title":"Front. Pharmacol."},{"key":"70898_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02022-x","volume":"21","author":"P He","year":"2023","unstructured":"He, P. et al. Advances in nanomedicines for lymphatic imaging and therapy. J. Nanobiotechnology 21, 292 (2023).","journal-title":"J. Nanobiotechnology"},{"key":"70898_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41577-023-00965-8","volume":"24","author":"P Cruz de Casas","year":"2024","unstructured":"Cruz de Casas, P., Kn\u00f6pper, K., Dey Sarkar, R. & Kastenm\u00fcller, W. Same yet different - how lymph node heterogeneity affects immune responses. Nat. Rev. Immunol. 24, 358\u2013374 (2024).","journal-title":"Nat. Rev. Immunol."},{"key":"70898_CR55","doi-asserted-by":"publisher","first-page":"1616794","DOI":"10.3389\/fimmu.2025.1616794","volume":"16","author":"H Liu","year":"2025","unstructured":"Liu, H. & Liang, Q. Single-cell multi-omics-based immune temporal network resolution in sepsis: unravelling molecular mechanisms and precise therapeutic targets. Front. Immunol. 16, 1616794 (2025).","journal-title":"Front. Immunol."},{"key":"70898_CR56","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","volume":"402","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo, A., Bathon, J. M. & Emery, P. Rheumatoid arthritis. Lancet 402, 2019\u20132033 (2023).","journal-title":"Lancet"},{"key":"70898_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3899\/jrheum.181398","volume":"47","author":"P Emery","year":"2020","unstructured":"Emery, P. et al. Longterm drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J. Rheumatol. 47, 493\u2013501 (2020).","journal-title":"J. Rheumatol."},{"key":"70898_CR58","doi-asserted-by":"publisher","first-page":"102392","DOI":"10.1016\/j.jaut.2019.102392","volume":"110","author":"MAM van Delft","year":"2020","unstructured":"van Delft, M. A. M. & Huizinga, T. W. J. An overview of autoantibodies in rheumatoid arthritis. J. Autoimmun. 110, 102392 (2020).","journal-title":"J. Autoimmun."},{"key":"70898_CR59","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1084\/jem.20030152","volume":"198","author":"W Chen","year":"2003","unstructured":"Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875\u20131886 (2003).","journal-title":"J. Exp. Med."},{"key":"70898_CR60","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","volume":"105","author":"M Battaglia","year":"2005","unstructured":"Battaglia, M., Stabilini, A. & Roncarolo, M. G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105, 4743\u20134748 (2005).","journal-title":"Blood"},{"key":"70898_CR61","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/anie.201410223","volume":"54","author":"G Chen","year":"2015","unstructured":"Chen, G. et al. Transformation of cell-derived microparticles into quantum-dot-labeled nanovectors for antitumor siRNA delivery. Angew. Chem. Int. Ed. Engl. 54, 1036\u20131040 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"70898_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20723-x","volume":"12","author":"Z Wei","year":"2021","unstructured":"Wei, Z. et al. Boosting anti-PD-1 therapy with metformin-loaded macrophage-derived microparticles. Nat. Commun. 12, 440 (2021).","journal-title":"Nat. Commun."},{"key":"70898_CR63","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"70898_CR64","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1365-2559.2006.02508.x","volume":"49","author":"V Krenn","year":"2006","unstructured":"Krenn, V. et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. Histopathology 49, 358\u2013364 (2006).","journal-title":"Histopathology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70898-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70898-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:06:51Z","timestamp":1778425611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-70898-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["70898"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-70898-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4170"}}